Keros Therapeutics considers sale amid investor pressure [Yahoo! Finance]
Keros Therapeutics, Inc. - common stock (KROS)
Company Research
Source: Yahoo! Finance
The move comes after certain investors – including one individual holding 11.2% of Keros's outstanding common stock as of 6 April 2025 – expressed a desire to shape the company's strategic decisions. US-based Keros stated that the limited-duration stockholder rights plan is designed to protect the integrity of its ongoing strategic review process, which could include the potential sale of the company. As a result of the announcement, Keros's shares jumped by 13%, reaching $11.67 per share at market open. The company confirmed it has initiated a process to evaluate strategic alternatives and plans to provide updates on the process within 60 days of the 10 April announcement. This update follows a series of challenges faced by Keros related to its cibotercept clinical programme for pulmonary arterial hypertension (PAH). In December 2024, Keros halted higher-dose cohorts from the Phase II TROPOS study (NCT05975905) after a safety review revealed concerning adverse events, includin
Show less
Read more
Impact Snapshot
Event Time:
KROS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KROS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KROS alerts
High impacting Keros Therapeutics, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
KROS
News
- KROS vs. ARGX: Which Stock Is the Better Value Option? [Yahoo! Finance]Yahoo! Finance
- Keros Therapeutics (NASDAQ:KROS) had its price target raised by analysts at Bank of America Corporation from $18.00 to $19.00. They now have a "neutral" rating on the stock.MarketBeat
- How Much Upside is Left in Keros Therapeutics (KROS)? Wall Street Analysts Think 34.24% [Yahoo! Finance]Yahoo! Finance
- Keros Therapeutics Announces Final Results of Tender Offer [Yahoo! Finance]Yahoo! Finance
- Keros Therapeutics Announces Final Results of Tender OfferGlobeNewswire
KROS
Earnings
- 11/5/25 - Beat
KROS
Sec Filings
- 12/18/25 - Form 4
- 12/18/25 - Form 4
- 12/18/25 - Form 4
- KROS's page on the SEC website